VERONA PHARMA
VRNANext catalyst
Ensifentrine
COPD
Get an email about VRNA's next catalysts
Track VERONA PHARMA (VRNA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 0 past
Ensifentrine Phase 2 Est. Readout
Estimated primary completion for Ensifentrine trial (NCT05270525) in COPD. Topline data typically follows completion by weeks to months.
SourceNebulized Ensifentrine Phase 2 Est. Readout
Primary completion for Nebulized Ensifentrine trial (NCT06559150) in Non-cystic Fibrosis Bronchiectasis
SourceMarket Overview
Stock performance and key metrics
Ensifentrine
Chronic Obstructive Pulmonary Disease
RPL554 suspension
COPD
Nebulized Ensifentrine
Non-cystic Fibrosis Bronchiectasis
Tiotropium/olodaterol (Respimat)
COPD
RPL554
Cystic Fibrosis
Glycopyrrolate
Chronic Obstructive Pulmonary Disease
RPL554 plus tiotropium
Chronic Obstructive Pulmonary Disease Moderate
LABA/LAMA
Pulmonary Disease, Chronic Obstructive, COPD
Formoterol
Chronic Obstructive Pulmonary Disease
Salbutamol
Chronic Obstructive Pulmonary Disease
Ensifentrine (marketed formulation)
Chronic Obstructive Pulmonary Disease
Ensifentrine Dose 1
Coronavirus Infection
Ipratropium
Chronic Obstructive Pulmonary Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ensifentrine | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
RPL554 suspension | Phase 2 | COPD | - | - |
Nebulized Ensifentrine | Phase 2 | Non-cystic Fibrosis Bronchiectasis | - | - |
Tiotropium/olodaterol (Respimat) | Phase 2 | COPD | - | - |
RPL554 | Phase 2 | Cystic Fibrosis | - | - |
Glycopyrrolate | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
RPL554 plus tiotropium | Phase 2 | Chronic Obstructive Pulmonary Disease Moderate | - | - |
LABA/LAMA | Phase 2 | Pulmonary Disease, Chronic Obstructive, COPD | - | - |
Formoterol | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Salbutamol | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Ensifentrine (marketed formulation) | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Ensifentrine Dose 1 | Phase 2 | Coronavirus Infection | - | - |
Ipratropium | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Frequently asked questions
What is in VERONA PHARMA's drug pipeline?→
CatalystAlert tracks 13 drug candidates in VERONA PHARMA's (VRNA) pipeline across Phase 3, Phase 2. Its lead program is Ensifentrine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VERONA PHARMA's next FDA catalyst?→
VERONA PHARMA's (VRNA) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VRNA biotech catalysts?→
Add VRNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VERONA PHARMA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.